RCT: Trastuzumab Deruxtecan vs. Trastuzumab Emtansine for breast cancer.
28 Mar, 2022 | 08:48h | UTCTrastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Trastuzumab Deruxtecan Ups PFS in HER2+ Metastatic Breast Cancer – HealthDay
Commentary on Twitter
In patients with metastatic HER2+ breast cancer that progressed after primary therapy, treatment with trastuzumab deruxtecan resulted in a higher response rate and longer progression-free survival than trastuzumab emtansine. https://t.co/R5suUeMLgE pic.twitter.com/yMiGrJw71U
— NEJM (@NEJM) March 24, 2022